ABC on COLD-fX
This article was originally published in The Tan Sheet
Executive Summary
A "major scientific review" of COLD-fX Pharmaceuticals' eponymous product finds the cold and flu remedy provides "impressive benefits," according to a March 1 release from the American Botanical Council. The review of published scientific and clinical studies on the product's active ingredient CVT-E002 found evidence that the product may offer prevention efficacy and suggest the product may help prevent acute respiratory infection. CVT-E002 is a proprietary herbal preparation made from the roots of North American ginseng. Bruce Barrett, M.D., University of Wisconsin, et al., also conclude they "could find no evidence of any risks that would require label warnings." COLD-fX is promoted by the National Hockey League (1"The Tan Sheet" Oct. 23, 2006, In Brief)...
You may also be interested in...
NDA For Cold-fX Could Follow Trial On Treating Cancer-Related Infections
CV Technologies would consider submitting a new drug application for its American ginseng extract following a National Cancer Institute-sponsored phase III trial on the effects of the ingredient on acute respiratory infection in certain leukemia patients
NHL promotes COLD-fX
The National Hockey League and the NHL Player's Association have entered into a multi-year partnership under which it will promote COLD-fX Pharmaceuticals' immune-enhancing supplement Cold-fX+. The product will be named the "official immune enhancer of the NHL and the NHLPA." In addition, six-time Stanley Cup Champion Mark Messier has signed on as an official spokesperson. Cold-fX recently entered the U.S. market following years of sale in Canada, and contains a patented natural extract consisting of distinctive polysaccharides that are isolated from Panax quinquefolius...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.